Enzyme Replacement Therapy Market Size, Share, Trends, Growth, Production, Consumption, Revenue, Company Analysis and Forecast 2021-2028

Chapter 1.  Introduction

1.1.  Research Objective

1.2.  Scope of the Study

1.3.  Definition

Chapter 2.  Research Methodology

2.1.  Research Approach

2.2.  Data Sources

2.3.  Assumptions & Limitations

Chapter 3.  Executive Summary

3.1.  Market Snapshot

Chapter 4.  Market Variables and Scope

4.1.  Introduction

4.2.  Market Classification and Scope

4.3.  Industry Value Chain Analysis

4.3.1.    Raw Material Procurement Analysis

4.3.2.    Sales and Distribution Channel Analysis

4.3.3.    Downstream Buyer Analysis

Chapter 5.  Market Dynamics Analysis and Trends

5.1.  Market Dynamics

5.1.1.    Market Drivers

5.1.2.    Market Restraints

5.1.3.    Market Opportunities

5.2.  Porter’s Five Forces Analysis

5.2.1.    Bargaining power of suppliers

5.2.2.    Bargaining power of buyers

5.2.3.    Threat of substitute

5.2.4.    Threat of new entrants

5.2.5.    Degree of competition

Chapter 6.  Competitive Landscape

6.1.1.    Company Market Share/Positioning Analysis

6.1.2.    Key Strategies Adopted by Players

6.1.3.    Vendor Landscape

6.1.3.1.        List of Suppliers

6.1.3.2.        List of Buyers

Chapter 7.  Global Enzyme Replacement Therapy Market, By Enzyme

7.1.  Enzyme Replacement Therapy Market, By Enzyme, 2020-2028

7.1.1.    Imiglucerase

7.1.1.1.        Market Revenue and Forecast (2016-2028)

7.1.2.    Agalsidase Beta

7.1.2.1.        Market Revenue and Forecast (2016-2028)

7.1.3.    Taliglucerase

7.1.3.1.        Market Revenue and Forecast (2016-2028)

7.1.4.    Velaglucerase Alfa

7.1.4.1.        Market Revenue and Forecast (2016-2028)

7.1.5.    Laronidase

7.1.5.1.        Market Revenue and Forecast (2016-2028)

7.1.6.    Alglucosidase Alfa

7.1.6.1.        Market Revenue and Forecast (2016-2028)

7.1.7.    Galsulfase

7.1.7.1.        Market Revenue and Forecast (2016-2028)

7.1.8.    Idursulfase

7.1.8.1.        Market Revenue and Forecast (2016-2028)

7.1.9.    Pancreatic Enzymes

7.1.9.1.        Market Revenue and Forecast (2016-2028)

7.1.10.  Pegademase

7.1.10.1.      Market Revenue and Forecast (2016-2028)

7.1.11.  Others

7.1.11.1.      Market Revenue and Forecast (2016-2028)

Chapter 8.  Global Enzyme Replacement Therapy Market, By Therapeutic Condition

8.1.  Enzyme Replacement Therapy Market, By Therapeutic Condition, 2020-2028

8.1.1.    Gaucher Disease

8.1.1.1.        Market Revenue and Forecast (2016-2028)

8.1.2.    Fabry Disease

8.1.2.1.        Market Revenue and Forecast (2016-2028)

8.1.3.    Pompe Disease

8.1.3.1.        Market Revenue and Forecast (2016-2028)

8.1.4.    SCID

8.1.4.1.        Market Revenue and Forecast (2016-2028)

8.1.5.    MPS

8.1.5.1.        Market Revenue and Forecast (2016-2028)

Chapter 9.  Global Enzyme Replacement Therapy Market, By End User

9.1.  Enzyme Replacement Therapy Market, by End User, 2020-2028

9.1.1.    Hospitals

9.1.1.1.        Market Revenue and Forecast (2016-2028)

9.1.2.    Infusion Centers

9.1.2.1.        Market Revenue and Forecast (2016-2028)

9.1.3.    Others

9.1.3.1.        Market Revenue and Forecast (2016-2028)

Chapter 10.      Global Enzyme Replacement Therapy Market, By Route of Administration

10.1.        Enzyme Replacement Therapy Market, By Route of Administration, 2020-2028

10.1.1.  Oral

10.1.1.1.      Market Revenue and Forecast (2016-2028)

10.1.2.  Parenteral

10.1.2.1.      Market Revenue and Forecast (2016-2028)

Chapter 11.      Global Enzyme Replacement Therapy Market, Regional Estimates and Trend Forecast

11.1.        North America

11.1.1.  Market Revenue and Forecast, By Enzyme (2016-2028)

11.1.2.  Market Revenue and Forecast, By Therapeutic Condition (2016-2028)

11.1.3.  Market Revenue and Forecast, by End User (2016-2028)

11.1.4.  Market Revenue and Forecast, By Route of Administration (2016-2028)

11.1.5.  U.S.

11.1.5.1.      Market Revenue and Forecast, By Enzyme (2016-2028)

11.1.5.2.      Market Revenue and Forecast, By Therapeutic Condition (2016-2028)

11.1.5.3.      Market Revenue and Forecast, by End User (2016-2028)

11.1.5.4.      Market Revenue and Forecast, By Route of Administration (2016-2028)

11.1.6.  Rest of North America

11.1.6.1.      Market Revenue and Forecast, By Enzyme (2016-2028)

11.1.6.2.      Market Revenue and Forecast, By Therapeutic Condition (2016-2028)

11.1.6.3.      Market Revenue and Forecast, by End User (2016-2028)

11.1.6.4.      Market Revenue and Forecast, By Route of Administration (2016-2028)

11.2.        Europe

11.2.1.  Market Revenue and Forecast, By Enzyme (2016-2028)

11.2.2.  Market Revenue and Forecast, By Therapeutic Condition (2016-2028)

11.2.3.  Market Revenue and Forecast, by End User (2016-2028)

11.2.4.  Market Revenue and Forecast, By Route of Administration (2016-2028)

11.2.5.  UK

11.2.5.1.      Market Revenue and Forecast, By Enzyme (2016-2028)

11.2.5.2.      Market Revenue and Forecast, By Therapeutic Condition (2016-2028)

11.2.5.3.      Market Revenue and Forecast, by End User (2016-2028)

11.2.5.4.      Market Revenue and Forecast, By Route of Administration (2016-2028)

11.2.6.  Germany

11.2.6.1.      Market Revenue and Forecast, By Enzyme (2016-2028)

11.2.6.2.      Market Revenue and Forecast, By Therapeutic Condition (2016-2028)

11.2.6.3.      Market Revenue and Forecast, by End User (2016-2028)

11.2.6.4.      Market Revenue and Forecast, By Route of Administration (2016-2028)

11.2.7.  France

11.2.7.1.      Market Revenue and Forecast, By Enzyme (2016-2028)

11.2.7.2.      Market Revenue and Forecast, By Therapeutic Condition (2016-2028)

11.2.7.3.      Market Revenue and Forecast, by End User (2016-2028)

11.2.7.4.      Market Revenue and Forecast, By Route of Administration (2016-2028)

11.2.8.  Rest of Europe

11.2.8.1.      Market Revenue and Forecast, By Enzyme (2016-2028)

11.2.8.2.      Market Revenue and Forecast, By Therapeutic Condition (2016-2028)

11.2.8.3.      Market Revenue and Forecast, by End User (2016-2028)

11.2.8.4.      Market Revenue and Forecast, By Route of Administration (2016-2028)

11.3.        APAC

11.3.1.  Market Revenue and Forecast, By Enzyme (2016-2028)

11.3.2.  Market Revenue and Forecast, By Therapeutic Condition (2016-2028)

11.3.3.  Market Revenue and Forecast, by End User (2016-2028)

11.3.4.  Market Revenue and Forecast, By Route of Administration (2016-2028)

11.3.5.  India

11.3.5.1.      Market Revenue and Forecast, By Enzyme (2016-2028)

11.3.5.2.      Market Revenue and Forecast, By Therapeutic Condition (2016-2028)

11.3.5.3.      Market Revenue and Forecast, by End User (2016-2028)

11.3.5.4.      Market Revenue and Forecast, By Route of Administration (2016-2028)

11.3.6.  China

11.3.6.1.      Market Revenue and Forecast, By Enzyme (2016-2028)

11.3.6.2.      Market Revenue and Forecast, By Therapeutic Condition (2016-2028)

11.3.6.3.      Market Revenue and Forecast, by End User (2016-2028)

11.3.6.4.      Market Revenue and Forecast, By Route of Administration (2016-2028)

11.3.7.  Japan

11.3.7.1.      Market Revenue and Forecast, By Enzyme (2016-2028)

11.3.7.2.      Market Revenue and Forecast, By Therapeutic Condition (2016-2028)

11.3.7.3.      Market Revenue and Forecast, by End User (2016-2028)

11.3.7.4.      Market Revenue and Forecast, By Route of Administration (2016-2028)

11.3.8.  Rest of APAC

11.3.8.1.      Market Revenue and Forecast, By Enzyme (2016-2028)

11.3.8.2.      Market Revenue and Forecast, By Therapeutic Condition (2016-2028)

11.3.8.3.      Market Revenue and Forecast, by End User (2016-2028)

11.3.8.4.      Market Revenue and Forecast, By Route of Administration (2016-2028)

11.4.        MEA

11.4.1.  Market Revenue and Forecast, By Enzyme (2016-2028)

11.4.2.  Market Revenue and Forecast, By Therapeutic Condition (2016-2028)

11.4.3.  Market Revenue and Forecast, by End User (2016-2028)

11.4.4.  Market Revenue and Forecast, By Route of Administration (2016-2028)

11.4.5.  GCC

11.4.5.1.      Market Revenue and Forecast, By Enzyme (2016-2028)

11.4.5.2.      Market Revenue and Forecast, By Therapeutic Condition (2016-2028)

11.4.5.3.      Market Revenue and Forecast, by End User (2016-2028)

11.4.5.4.      Market Revenue and Forecast, By Route of Administration (2016-2028)

11.4.6.  North Africa

11.4.6.1.      Market Revenue and Forecast, By Enzyme (2016-2028)

11.4.6.2.      Market Revenue and Forecast, By Therapeutic Condition (2016-2028)

11.4.6.3.      Market Revenue and Forecast, by End User (2016-2028)

11.4.6.4.      Market Revenue and Forecast, By Route of Administration (2016-2028)

11.4.7.  South Africa

11.4.7.1.      Market Revenue and Forecast, By Enzyme (2016-2028)

11.4.7.2.      Market Revenue and Forecast, By Therapeutic Condition (2016-2028)

11.4.7.3.      Market Revenue and Forecast, by End User (2016-2028)

11.4.7.4.      Market Revenue and Forecast, By Route of Administration (2016-2028)

11.4.8.  Rest of MEA

11.4.8.1.      Market Revenue and Forecast, By Enzyme (2016-2028)

11.4.8.2.      Market Revenue and Forecast, By Therapeutic Condition (2016-2028)

11.4.8.3.      Market Revenue and Forecast, by End User (2016-2028)

11.4.8.4.      Market Revenue and Forecast, By Route of Administration (2016-2028)

11.5.        Latin America

11.5.1.  Market Revenue and Forecast, By Enzyme (2016-2028)

11.5.2.  Market Revenue and Forecast, By Therapeutic Condition (2016-2028)

11.5.3.  Market Revenue and Forecast, by End User (2016-2028)

11.5.4.  Market Revenue and Forecast, By Route of Administration (2016-2028)

11.5.5.  Brazil

11.5.5.1.      Market Revenue and Forecast, By Enzyme (2016-2028)

11.5.5.2.      Market Revenue and Forecast, By Therapeutic Condition (2016-2028)

11.5.5.3.      Market Revenue and Forecast, by End User (2016-2028)

11.5.5.4.      Market Revenue and Forecast, By Route of Administration (2016-2028)

11.5.6.  Rest of LATAM

11.5.6.1.      Market Revenue and Forecast, By Enzyme (2016-2028)

11.5.6.2.      Market Revenue and Forecast, By Therapeutic Condition (2016-2028)

11.5.6.3.      Market Revenue and Forecast, by End User (2016-2028)

11.5.6.4.      Market Revenue and Forecast, By Route of Administration (2016-2028)

Chapter 12.  Company Profiles

12.1.              Shire Plc; Sanofi S.A.

12.1.1.  Company Overview

12.1.2.  Product Offerings

12.1.3.  Financial Performance

12.1.4.  Recent Initiatives

12.2.              Biomarin Pharmaceutical Inc.

12.2.1.  Company Overview

12.2.2.  Product Offerings

12.2.3.  Financial Performance

12.2.4.  Recent Initiatives

12.3.              AbbVie

12.3.1.  Company Overview

12.3.2.  Product Offerings

12.3.3.  Financial Performance

12.3.4.  Recent Initiatives

12.4.              Alexion Pharmaceuticals Inc.

12.4.1.  Company Overview

12.4.2.  Product Offerings

12.4.3.  Financial Performance

12.4.4.  Recent Initiatives

12.5.              Allergan plc

12.5.1.  Company Overview

12.5.2.  Product Offerings

12.5.3.  Financial Performance

12.5.4.  Recent Initiatives

12.6.              Horizon Pharma Public Limited Company

12.6.1.  Company Overview

12.6.2.  Product Offerings

12.6.3.  Financial Performance

12.6.4.  Recent Initiatives

12.7.              Actelion (Janssen)

12.7.1.  Company Overview

12.7.2.  Product Offerings

12.7.3.  Financial Performance

12.7.4.  Recent Initiatives

12.8.              Recordati Rare Diseases

12.8.1.  Company Overview

12.8.2.  Product Offerings

12.8.3.  Financial Performance

12.8.4.  Recent Initiatives

12.9.              Protalix Biotherapeutics

12.9.1.  Company Overview

12.9.2.  Product Offerings

12.9.3.  Financial Performance

12.9.4.  Recent Initiatives

12.10.           Amicus Therapeutics, Inc.

12.10.1.               Company Overview

12.10.2.               Product Offerings

12.10.3.               Financial Performance

12.10.4.               Recent Initiatives

Chapter 13.  Research Methodology

13.1.              Primary Research

13.2.              Secondary Research

13.3.              Assumptions

Chapter 14.  Appendix

14.1.              About Us

Glossary of Terms